| Gene symbol | PRAME | Synonyms | CT130, MAPE, OIP-4, OIP4 | Type of gene | protein-coding |
| Chromosome | 22 | Map location | 22q11.22 | dbXrefs | |
| Description | PRAME nuclear receptor transcriptional regulator | ||||
| GTO ID | GTC1608 |
| Trial ID | NCT02743611 |
| Disease | Uveal Melanoma | Acute Myeloid Leukemia | Myelodysplastic Syndrome |
| Altered gene | PRAME |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | BPX-701 |
| Co-treatment | Rimiducid |
| HLA | HLA-A*02:01 |
| Phase | Phase1|Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | A Phase 1/2 Dose-Finding Study to Evaluate the Safety, Feasibility, and Activity of BPX-701, a Controllable PRAME T-Cell Receptor Therapy, in HLA-A2+ Subjects With AML, Previously Treated MDS, or Metastatic Uveal Melanoma |
| Year | 2016 |
| Country | United States |
| Company sponsor | Bellicum Pharmaceuticals |
| Other ID(s) | BP-011 |
| Vector information | |||||||
|
|||||||
| Cohort 1 | |||||||||
|
|||||||||